RNAZ · Company research
TransCode Therapeutics, Inc. Common Stock (RNAZ): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
16records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| RNAZ Forecast — Price Target — Prediction for 2027 - TradingView | RNAZ Forecast — Price Target — Prediction for 2027 TradingView | View source ↗ | TradingView | Oct 5, 2026 | neutral | 0 | 0.6 |
| TransCode Therapeutics Eases Near-Term Obligations Under Financing - The Globe and Mail | TransCode Therapeutics Eases Near-Term Obligations Under Financing The Globe and Mail | View source ↗ | The Globe and Mail | Oct 2, 2026 | neutral | 0 | 0.6 |
| With a waiver through October 31, TransCode Therapeutics (RNAZ) pays Yorkville. - Stock Titan | With a waiver through October 31, TransCode Therapeutics (RNAZ) pays Yorkville. Stock Titan | View source ↗ | Stock Titan | Oct 1, 2026 | neutral | 0 | 0.6 |
| Three of 14 patients had no cancer progression at one year in an experimental drug trial - Stock Titan | Three of 14 patients had no cancer progression at one year in an experimental drug trial Stock Titan | View source ↗ | Stock Titan | Sep 28, 2026 | neutral | 0 | 0.6 |
| A cancer treatment technology gains a Japan patent. Australia may follow. - Stock Titan | A cancer treatment technology gains a Japan patent. Australia may follow. Stock Titan | View source ↗ | Stock Titan | Sep 22, 2026 | neutral | 0 | 0.6 |
| Transcode Therapeutics (RNAZ) interim CFO becomes reporting insider with no listed stake - Stock Titan | Transcode Therapeutics (RNAZ) interim CFO becomes reporting insider with no listed stake Stock Titan | View source ↗ | Stock Titan | Sep 21, 2026 | neutral | 0 | 0.6 |
| An RNA-based treatment showed a survival benefit in mice with breast cancer spread to bone - Stock Titan | An RNA-based treatment showed a survival benefit in mice with breast cancer spread to bone Stock Titan | View source ↗ | Stock Titan | Aug 31, 2026 | neutral | 0 | 0.6 |
| RNAZ Stock Price, Quote & News - Syfe | RNAZ Stock Price, Quote & News Syfe | View source ↗ | Syfe | Aug 28, 2026 | neutral | 0 | 0.6 |
| TransCode Therapeutics (RNAZ) Holds Above $3.50 as Shares Grind Higher in Quiet Session - Low Vol ETF - dars.gov.et | TransCode Therapeutics (RNAZ) Holds Above $3.50 as Shares Grind Higher in Quiet Session - Low Vol ETF dars.gov.et | View source ↗ | dars.gov.et | Aug 14, 2026 | neutral | 0 | 0.6 |
| Transcode Therapeutics Inc (NASDAQ: RNAZ) Share Price, RNAZ Stock News, RNAZ Share Price & Updates - Kalkine | Transcode Therapeutics Inc (NASDAQ: RNAZ) Share Price, RNAZ Stock News, RNAZ Share Price & Updates Kalkine | View source ↗ | Kalkine | Jul 15, 2026 | neutral | 0 | 0.6 |
| TransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of - PR Newswire | TransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of PR Newswire | View source ↗ | PR Newswire | Mar 3, 2026 | neutral | 0 | 0.6 |
| TransCode Therapeutics (RNAZ) announces the acquisition of Polynoma and a $25 Million strategic financing by a subsidiary of CK Life Sciences to form a first-in-class unique immuno-oncology and metastatic prevention oncology company - PR Newswire | TransCode Therapeutics (RNAZ) announces the acquisition of Polynoma and a $25 Million strategic financing by a subsidiary of CK Life Sciences to form a first-in-class unique immuno-oncology and metastatic prevention oncology company PR Newswire | View source ↗ | PR Newswire | Oct 8, 2025 | neutral | 0 | 0.6 |
| symbol__ Stock Quote Price and Forecast - CNN | symbol__ Stock Quote Price and Forecast CNN | View source ↗ | CNN | Jan 18, 2024 | neutral | 0 | 0.6 |
| Why Is TransCode Therapeutics (RNAZ) Stock Down 69% Today? - InvestorPlace | Why Is TransCode Therapeutics (RNAZ) Stock Down 69% Today? InvestorPlace | View source ↗ | InvestorPlace | Sep 26, 2023 | neutral | 0 | 0.6 |
| RNAZ: TransCode Therapeutics Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits | RNAZ: TransCode Therapeutics Inc Latest Stock Price, Analysis, News and Trading Ideas Stocktwits | View source ↗ | Stocktwits | Jul 12, 2021 | neutral | 0 | 0.6 |
| TransCode Therapeutics, Inc. (RNAZ) Stock Price, News, Quote & History - Yahoo! Finance Canada | TransCode Therapeutics, Inc. (RNAZ) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Apr 28, 2021 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.